Cagrilintide Peptide Therapy: A New Era in Appetite Control and Weight Revolution Health & Wellness ACC 2026: Meta analysis supports CagriSema as superior first line therapy in obesity Pharmaceutical Technology Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Novo's Phase 3 CagriSema results disappoint analysts, sending stock tumbling MM+M Medical Marketing and Media Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 eBioMedicine